Author + information
- Brian F. Gage, MD, MSc⁎ and
- Martha J. Radford, MD
- ↵⁎Washington University School of Medicine, Campus Box 8005, 660 South Euclid Avenue, St. Louis, Missouri 63110
The study by Apostolakis et al. (1) compares the performance of bleeding risk–prediction scores in AMADEUS participants randomized to receive a vitamin K antagonist but excludes the 2,283 participants who were randomized to receive idraparinux. Because most of the bleeds in AMADEUS occurred in participants randomized to receive idraparinux, the authors should also provide c-statistics for major bleeding from these participants. For a valid comparison, could they also provide c-statistics for major bleeding from AMADEUS participants randomized to vitamin K antagonists, using each prediction score as a continuous variable but not including INR variability? This variable is not available until after the decision to initiate a vitamin K antagonist has already been made.
Please note: Drs. Gage and Radford are originators of the HEMORR2HAGES risk-prediction score.
- 2013 American College of Cardiology Foundation
- Apostolakis S.,
- Lane D.A.,
- Guo Y.,
- Buller H.,
- Lip G.Y.